Safety and Efficacy of Six Months Dual Antiplatelet Therapy After Drug-Eluting Stenting

Inclusion Criteria: * Patients on clopidogrel therapy at 6 months (-1/+2 months) after DES implantation * Informed, written consent by the patient Exclusion Criteria: * Age ≤18 years * Clinically symptoms, proof of ischemia and/or presence of angiographic lesions requiring revascularization * Previous stent thrombosis * DES in left main coronary artery * ST-elevation and non-ST-elevation myocardial infarction during the last 6 months * Malignancies or other comorbid conditions with a life expectancy of less than one year or that may result in protocol noncompliance * Planned major surgery within the next 6 months with the need to discontinue antiplatelet therapy * Active bleeding; bleeding diathesis; history intracranial bleeding * Oral anticoagulation therapy with coumadin derivatives * Known allergy or intolerance to the study medications: aspirin and clopidogrel * Pregnancy (present, suspected or planned) or positive pregnancy test (In women with childbearing potential a negative pregnancy test is mandatory) * Patient's inability to fully comply with the study protocol * Prior enrollment in the same clinical trial.